[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-pre-exposure-prophylaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-pre-exposure-prophylaxis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,68,88,118,143,174,197,226,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639988","phase-1-a-clinical-trial-of-mk-8527-and-rifampin-in-adult-participants-with-latent-tuberculosis-infection-mk-8527-019-100639988",false,"NCT07600775","A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)","An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of untreated latent tuberculosis infection (LTBI)\n* Has no symptoms of active tuberculosis (TB)\n* Has never received treatment for TB or LTBI\n* Other than having LTBI, is in good health\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of LTBI made in the context of an outbreak\u002Fcontact-tracing investigation\n* Has a current or anticipated immunocompromised state\n* Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases\n* Has a history of cancer (malignancy)\n* Has a history of active TB\n* Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus","ALL","18 Years","60 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI).\n\nThe main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.",[27,28],"Human Immunodeficiency Virus (HIV)","HIV Pre-Exposure Prophylaxis","NOT_YET_RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":21},"2026-07-20",{"date":37,"type":21},"2027-01-19",{"name":39,"class":40},"Merck Sharp & Dohme LLC","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100598448","phase-3-a-study-of-mk-8527-to-prevent-human-immunodeficiency-virus-type-1-hiv-1-mk-8527-010-100598448","NCT07071623","A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is confirmed Human Immunodeficiency Virus (HIV)-uninfected based on negative HIV-1\u002FHIV-2 test results\n* Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months)\n* Was assigned female sex at birth and is cisgender.\n* Weighs ≥35 kg\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has hypersensitivity or other contraindication to any component of the study interventions\n* Has evidence of acute or chronic hepatitis B infection\n* Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time\n* Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration\n* Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1",true,"FEMALE","16 Years","30 Years",{"count":53,"type":21},4580,[55],"PHASE3","Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.\n\nThe goals of this study are to learn:\n\n* If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day\n* About the safety of MK-8527 and if people tolerate it",[27,28],"RECRUITING","2026-06-26",{"date":61,"type":33},"2026-06-29",{"date":63,"type":33},"2025-11-10",{"date":65,"type":21},"2027-10-18",{"name":39,"class":40},30,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":48,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100596349","phase-3-a-clinical-study-of-mk-8527-to-prevent-human-immunodeficiency-virus-type-1-hiv-1-mk-8527-011-100596349","NCT07044297","A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is confirmed HIV-uninfected based on negative HIV-1\u002FHIV-2 test results\n* Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person\n* Has had condomless receptive anal sex in the 12 months prior to screening (not including sex occurring in a mutually monogamous relationship) and has at least 1 of the following: receptive anal sex with 2 or more partners in the 3 months prior to screening (regardless of condom use), rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening, or any self-reported stimulant drug use with sex in the 3 months prior to screening\n* Weighs ≥35 kg\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has hypersensitivity or other contraindication to any component of the study interventions\n* Has evidence of acute or chronic hepatitis B infection\n* Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers\n* Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time\n* Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration\n* Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1\n* Is expecting to donate eggs at any time during the study",{"count":76,"type":21},4390,[55],"Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.\n\nThe goals of this study are to learn:\n\n* If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day\n* About the safety of MK-8527 and if people tolerate it",[27,28],"2026-06-25",{"date":61,"type":33},{"date":83,"type":33},"2025-07-31",{"date":85,"type":21},"2027-07-22",{"name":39,"class":40},81,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":48,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":117},"100599859","hiv-testing-counselor-led-care-to-catalyze-integration-of-prep-delivery-in-family-planning-clinics-100599859","NCT07089966","HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics","HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics: The HIV Testing Services PrEP Integration (HTS PrEP) Project","HTS PrEP","Inclusion Criteria:\n\n* ≥15 years of age\n* Accessing health services at participating public health facilities.\n* Not known to be living with HIV prior to the visit when their clinical data is first abstracted","15 Years",{"count":98,"type":21},30000,[100],"NA","This is a cluster randomized, stepped wedge implementation study to introduce HIV testing services (HTS) counselor-led PrEP care in public health clinics in Kenya.",[27,103],"HIV Pre-exposure Prophylaxis",[105,106],"PrEP","HIV Prevention","2026-06-16",{"date":109,"type":33},"2026-06-18",{"date":111,"type":33},"2025-12-01",{"date":113,"type":21},"2029-06-30",{"name":115,"class":116},"University of Washington","OTHER",1,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":117},"100628513","hiv-pre-exposure-prophylaxis-prep-linkage-with-immediate-medications-in-the-emergency-department-study-100628513","NCT07462611","HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study","HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department (PrEP-ED) Study","PrEP ED","Primary study (ED patients):\n\nInclusion Criteria:\n\n* Able to comprehend and provide signed, written informed consent prior to initiation of study procedures.\n* Negative HIV rapid test\n* At least one of the following criteria:\n\n  * Requesting PrEP from their ED clinician\n  * Score \\>75% on the PCCI HIV Prediction Tool\n  * Prior bacterial STI diagnosis\n  * Seeking STI testing\n  * Referred by their ED clinician as someone who otherwise meets a CDC PrEP indication\n\nExclusion Criteria:\n\n* Known diagnosis of HIV\n* Positive HIV rapid test\n* Current use of PrEP, which is defined for purposes of this study as use of PrEP in the last 4 weeks\n* Known hypersensitivity or allergy to any PrEP modality\n* People who do not want to follow with Parkland ID clinic for ongoing PrEP care\n* Adults unable to consent, people under the age of 18, women who are known to be pregnant or breast feeding at time of study enrollment, or prisoners\n\nSub-study subjects (ED clinicians):\n\nInclusion criteria:\n\n• Clinician in the Parkland ED\n\nExclusion criteria:\n\n• People under the age of 18 or prisoners.",{"count":127,"type":21},250,[100],"Our primary objective is to increase HIV pre-exposure prophylaxis (PrEP) awareness and uptake among people who want, need, or would benefit from PrEP in Dallas, TX through a pilot program of immediate PrEP prescribing in the Parkland Memorial Hospital Emergency Department (ED) with linkage to PrEP clinic. Leveraging the previous work of the Parkland Center for Clinical Innovation (PCCI) which created an automated electronic health record (EHR) based HIV prediction tool and prior success with a robust ED HIV navigation program, a PrEP navigator would approach patients in the Parkland ED for PrEP initiation. Through standard care prescribing by their ED clinician, subjects would leave the ED with a prescription for rapid-start oral PrEP and a clinic appointment to persist on the PrEP modality of their choice which will include long-acting injectable options.",[103,105],[105,132,133],"HIV pre-exposure prophylaxis","Emergency department","2026-05-29",{"date":136,"type":33},"2026-06-02",{"date":138,"type":33},"2026-04-08",{"date":140,"type":21},"2028-04-01",{"name":142,"class":116},"University of Texas Southwestern Medical Center",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":48,"sex":151,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":117},"100609717","phase-4-enhancing-prep-uptake-and-retention-among-latine-tgw-and-gbm-in-the-south-using-long-acting-injectable-prep-100609717","NCT07218211","Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP","INCLUSION - Enhancing PrEP Uptake and Retention Among Latine Transgender Women and Gay, Bisexual, and Other Men Who Have Sex With Men in the South Using Long-Acting Injectable PrEP","INCLUSION","Inclusion Criteria:\n\n* Participants must be assigned male sex at birth.\n* Report sexual activity with a someone assigned male at birth OR identify as GBM or TGW; be HIV-negative.\n* Identify as Hispanic and\u002For Latine .\n* Be able to provide informed consent in English or Spanish .\n* Be 18 years or older .\n* Weigh at least 77 lbs (35 kg) by self-reported weight.\n* Interested in PrEP and willing to undergo the study procedures.\n\nExclusion Criteria:\n\n* Individuals living with HIV.\n* Individuals assigned female sex at birth will be excluded.\n* Individuals who are currently taking oral PrEP from another source and are not willing to switch to lenacapavir for PrEP for the duration of the study will also be excluded.\n* Individuals who report a history of severe renal or hepatic disease or with clinical stigmata of either disease on physical exam as assessed by a study clinician will be excluded.\n* Individuals taking a medication with a significant interaction with lenacapavir will be excluded from the study.","MALE",{"count":153,"type":21},100,[155],"PHASE4","The purpose of this project is to test a culturally-tailored, community-delivered long-acting injectable PrEP (lenacapavir) program for Latine gay and bisexual men (GBM) and transgender women (TGW). The objective is to evaluate whether this intervention demonstrates greater persistence on lenacapavir for Latine GBM and TGW compared with what has been observed historically at the Duke PrEP Clinic.",[106,103,158,159,160],"HIV Prevention Program","HIV Prevention and Care","HIV Pre-exposure Prophylaxis Use",[162,163,105,164],"Long-acting Injectable PrEP","Lenacapavir","PrEP injections","2026-01-29",{"date":167,"type":33},"2026-02-02",{"date":169,"type":33},"2026-01-13",{"date":171,"type":21},"2028-01-05",{"name":173,"class":116},"Duke University",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":184,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100622133","long-acting-injectable-hiv-prep-pros-100622133","NCT07379658","Long-Acting Injectable HIV PrEP PROs","Improving HIV Prevention Outcomes: Insights on Long-Acting Injectable (LAI) HIV Pre-Exposure Prophylaxis (PrEP) Patient-Reported Medication Preferences, Adherence, and Clinical Outcomes (IMPACT) in a Southern US State","IMPACT","Inclusion Criteria:\n\n1. Adults aged 18 and older\n2. Deemed eligible for HIV PrEP per healthcare provider\n3. Receiving or initiating LAI PrEP, defined as:\n\n   1. Current use of CAB or LEN LAI PrEP at study entry\n   2. Initiation of either CAB or LEN LAI PrEP within 30 days of study enrollment\n4. Receiving PrEP services in Louisville, KY\n5. Able to provide informed consent and complete study assessments\n\nExclusion Criteria:\n\n1. HIV diagnosis prior to enrollment\n2. Currently on oral PrEP with no plans to switch to LAI PrEP\n3. Hypersensitivities to LEN or CAB\n4. Pregnant or planning to become pregnant\n5. PI discretion",{"count":183,"type":21},128,"OBSERVATIONAL","The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews.\n\nParticipants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.",[103],"2026-01-23",{"date":189,"type":33},"2026-01-30",{"date":191,"type":21},"2026-01-15",{"date":193,"type":21},"2028-01",{"name":195,"class":116},"Anupama Raghuram MD",3,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":117},"100577546","trauma-informed-resilience-based-telehealth-intervention-for-improving-hiv-prevention-and-hcv-care-for-persons-who-inject-drugs-in-the-deep-south-pilot-testing-aim3-100577546","NCT06799702","Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)","Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South","Inclusion Criteria:\n\n* People who actively inject drugs verified by visible injection stigmata (needle tracks)\n* HIV negative\n* Adult (≥18 years)\n* lives in rural areas\n\nExclusion Criteria:\n\n* Living with HIV\n* Lives in urban areas\n* Not proficient in English",{"count":205,"type":21},50,[100],"Evaluate the feasibility, acceptability, and usability of the intervention (primary outcomes) and coping skills and resilience (secondary outcomes) of the telehealth intervention over two months (8 weekly sessions) in a waitlist-controlled, randomized pilot trial using a cross-over design among 40 PWID. The primary outcomes will be feasibility, acceptability, and usability of the intervention. Secondary outcomes will be increased coping skills and resilience, which in turn, will increase status neutral HIV and HCV care and MOUD uptake (longer-term outcomes). Outcomes will be assessed using pre- and post-intervention surveys.",[103,209,210],"HEPATITIS C (HCV)","Opioid Use Disorder",[28,212,213,214,215,216],"Hepatitis C Virus","Medications for Opioid Use Disorder","People who inject drugs (PWID)","Deep South","Telehealth Intervention","2025-12-17",{"date":219,"type":33},"2025-12-18",{"date":221,"type":21},"2026-08-01",{"date":223,"type":21},"2028-07-31",{"name":225,"class":116},"University of Georgia",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":48,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":117},"100606304","optimizing-prep-uptake-for-african-american-women-in-the-south-by-empowering-women-to-make-informed-hiv-prevention-and-sexual-health-choices-100606304","NCT07173816","Optimizing PrEP Uptake for African American Women in the South by Empowering Women to Make Informed HIV Prevention and Sexual Health Choices","EMPOWER","Inclusion Criteria:\n\n1. Identification as cis-gendered Black woman;\n2. Age 18 and older;\n3. Engaging in risky sexual behavior in prior 3 months (condomless vaginal or anal sex with a non-main partner, or a partner with known or suspected risk behavior such as injection drug use or HIV\u002FSTI, multiple sex partners, transactional sex);\n4. Access to a device with a screen, a web browser, and adequate internet speed (e.g., smartphone, computer) for videoconferencing;\n5. Able to speak and read English; and\n6. No plans to leave the Atlanta, GA area during the duration of study participation.\n\nExclusion Criteria:\n\n1. Cognitive or mental health condition that limits the ability to provide informed consent;\n2. Self-reported use of PrEP or PEP medication in the past three months;\n3. Unable to speak and read English; and\n4. Currently living with HIV.",{"count":234,"type":21},80,[100],"Pilot testing of EMPOWER, a group sexual health intervention, to increase uptake and persistence of PrEP",[103],"2025-09-10",{"date":240,"type":33},"2025-09-15",{"date":221,"type":21},{"date":243,"type":21},"2027-08-31",{"name":225,"class":116},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":253,"enrollmentInfo":254,"targetDuration":256,"studyType":184,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":117},"100464312","vienna-hiv-infection-via-sex-study-100464312","NCT05326061","Vienna HIV Infection Via Sex Study","Characterization of Patients at High Risk for the Acquisition of Sexually Transmitted Infection With the Human Immunodeficiency Virus (HIV) - a Clinical Study","HIVEX","Inclusion Criteria:\n\n1. High risk for acquiring HIV defined as followed: HIV-negative MSM and transgender individuals who (i) do not use condoms consistently with casual partners and\u002For with HIV-positive partners who are not on treatment and\u002For (ii) recently acquired an STI and\u002For (iii) recently used PEP and\u002For (iv) frequently engage in 'chemsex'.\n2. Age \\>18 years and \\\u003C100 years.\n3. Written informed consent for this registry study.\n\nExclusion Criteria:\n\n1\\. Withdrawal of the written informed consent.","100 Years",{"count":255,"type":21},500,"5 Years","The main objective of this prospective observational cohort study is to investigate the epidemiology, the risk factors and ultimately the incidence of novel HIV infections among individuals at high risk for acquiring HIV via sex practices.",[259,28,260,261,262,263],"HIV Infections","Sexually Transmitted Diseases","Gonorrhea","Chlamydia","Syphilis","2022-04-06",{"date":266,"type":33},"2022-04-13",{"date":268,"type":33},"2020-07-01",{"date":270,"type":21},"2030-12",{"name":272,"class":116},"Medical University of Vienna"]